Skip to Main content Skip to Navigation
Journal articles

Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab-irinotecan in children with low-grade glioma?

Abstract : The association of bevacizumab and irinotecan has been shown to display a quick efficacy in low- grade glioma (LGG), but most patients relapse within months after cessation of therapy. From October 2012 to March 2014, four patients have been treated with irinotecan–bevacizumab followed by a metronomic maintenance with weekly vinblastine to try to prevent relapses. After a median follow- up of 23 months after the end of the bevacizumab–irinotecan induction, no patient relapsed. These observations suggest that maintenance chemotherapy with weekly vinblastine after an induction by irinotecan–bevacizumab can improve progression-free survival in children with LGG.
Complete list of metadatas

Cited literature [14 references]  Display  Hide  Download

https://hal-amu.archives-ouvertes.fr/hal-01478943
Contributor : Dominique Figarella-Branger <>
Submitted on : Tuesday, February 28, 2017 - 2:58:59 PM
Last modification on : Wednesday, August 19, 2020 - 12:08:13 PM
Long-term archiving on: : Monday, May 29, 2017 - 3:43:18 PM

File

Heng et al_2016.pdf
Publisher files allowed on an open archive

Identifiers

Collections

Citation

Marie Amélie Heng, Laetitia Padovani, Philippe Dory-Lautrec, Jean Claude Gentet, Arnaud Verschuur, et al.. Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab-irinotecan in children with low-grade glioma?. Cancer Medicine, Wiley, 2016, 5 (7), pp.1542-1545. ⟨10.1002/cam4.699⟩. ⟨hal-01478943⟩

Share

Metrics

Record views

209

Files downloads

335